Clinical trials: Infection Risk
SARS-CoV-2
COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease
Primary Objectives Phase 1 (Safety and Tolerability) Evaluate the safety and tolerability of REGN14256+imdevimab and REGN14256 monotherapy, as measured by treatment-emergent adverse events (TEAEs), injection-site reactions…
- Trial name
- NCT05081388
- Testing
- REGN14256, imdevimab, casirivimab + imdevimab
- Where
- 28 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Influenza
High-risk Influenza Vaccine Alert
The purpose of this study is to assess, prospectively, the effect on flu vaccination rates of salient alerts in the electronic health record that indicate a patient's high risk for flu and its complications.
- Trial name
- NCT05492786
- Testing
- Alert, Salient alert features, High-risk Text
- Where
- United States
- Volunteers
- 80,452 people
- Sponsor
- Geisinger Clinic
HIV Infections, Viremia
Enhanced Virologic Monitoring for Pregnant and Postpartum Women With HIV
The goal of this study is to learn about supporting pregnant and postpartum women living with HIV with treatment adherence. The investigators will conduct a pilot study of an intervention that includes peer counseling about viral…
- Conditions
- HIV Infections, Viremia, Pregnancy Related
- Trial name
- NCT05845619
- Testing
- Enhanced virologic monitoring
- Where
- 4 sites in Kenya
- Volunteers
- 550 people
- Sponsor
- University of California, San Francisco
Sexually Transmitted Disease, Bacterial Vaginosis
Women's Improvement of Sexual Health (WISH) Demonstration Project
The current standard of care for urogenital infections in Rwanda is syndromic management. Many urogenital infections are asymptomatic and therefore completely missed, and the management of vaginal discharge syndrome is known to…
- Conditions
- Sexually Transmitted Disease, Bacterial Vaginosis, Vaginal Candidiasis, Urinary Tract Infections
- Trial name
- WISH (NCT03045809)
- Testing
- Urogenital infection point-of-care tests
- Where
- Rwanda
- Volunteers
- 705 people, healthy volunteers welcome
- Sponsor
- Janneke van de Wijgert
HIV Infection
A Safety and Immune Response Study of 2 Experimental HIV Vaccines
The HIV Vaccine Trials Network (HVTN) is doing a study to test a new HIV vaccine combination. HIV is the virus that causes AIDS. 252 people are taking part in this study at multiple sites.
- Trial name
- NCT02404311
- Testing
- ALVAC-HIV, Bivalent Subtype C gp120/MF59®
- Where
- 5 sites in South Africa
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
The purpose of this study is to determine whether PF-07321332/ritonavir is safe and effective for the treatment of adults who are ill with COVID-19 and do not need to be in the hospital, but are at an increased risk of developing…
- Trial name
- NCT04960202
- Testing
- PF-07321332, Ritonavir
- Where
- 201 sites in United States, Argentina and 18 more
- Volunteers
- 2,091 people
- Sponsor
- Pfizer
Influenza, Influenza Vaccines
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
The purpose of this study is to evaluate the safety and tolerability of GSK Biologicals' vaccine GSK1557484A against pandemic avian (H5N1) influenza in adults at occupational risk of exposure to the virus.
- Trial name
- NCT01788228
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection
The purpose of this study was to evaluate the safety and pharmacokinetics (PK) of raltegravir (RAL) when given to HIV-1-exposed, normal birth weight newborn infants at risk of acquiring HIV-1 infection.
- Trial name
- NCT01780831
- Testing
- Raltegravir
- Where
- 15 sites in United States, Brazil and 3 more
- Volunteers
- 52 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Acquired Immunodeficiency Syndrome
A Unified Intervention for Young Gay and Bisexual Men's Minority Stress, Mental Health, and HIV Risk
The intent of the proposed randomized controlled trial is to test the efficacy of a principle-based, transdiagnostic cognitive behavioral therapy (CBT) intervention that addresses the pathways through which minority stress…
- Trial name
- NCT02929069
- Testing
- ESTEEM, CMHT, VCT
- Where
- 2 sites in United States
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Yale University
Cardiovascular Disease, HIV Infection
Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial
The purpose of this study is to determine whether fish oil supplementation with Lovaza, formally known as Omacor will result in a significant reduction in serum triglyceride (TG), an increase in high density lipoproteins(HDL)…
- Trial name
- HALO (NCT00795717)
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Tufts University
Adenovirus Infection, BK Virus Infection
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
This is a Phase 3 study to evaluate posoleucel (ALVR105, Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- Prevent (NCT05305040)
- Testing
- Posoleucel (ALVR105)
- Where
- 88 sites in United States, Australia and 8 more
- Volunteers
- 451 people
- Sponsor
- AlloVir
Influenza, Vaccination
Encouraging Flu Vaccination Among High-Risk Patients Identified by ML
The purpose of the current study is to test different interventions to determine the most effective way to promote flu vaccine uptake in a high-risk population identified by an "artificial intelligence" (AI) or machine learning…
- Conditions
- Influenza, Vaccination, Health Promotion, Health Behavior
- Trial name
- NCT04323137
- Testing
- Risk reduction, Medical records-based recommendation, Algorithm-based recommendation
- Where
- United States
- Volunteers
- 117,649 people
- Sponsor
- Geisinger Clinic
Pneumonia, Viral
Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS
The goal of this study is to evaluate the effects of Ibudilast (MN-166) versus placebo in hospitalized patients infected with COVID-19 at risk for developing acute respiratory distress syndrome (ARDS) receiving standard of care…
- Trial name
- NCT04429555
- Testing
- Ibudilast
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- MediciNova
COVID-19
Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness
The goal of this clinical study is to test how well the study drug, obeldesivir (GS-5245), works and how safe it is in treating coronavirus disease 2019 (COVID-19) in participants that have a higher risk of getting a serious…
- Trial name
- BIRCH (NCT05603143)
- Testing
- Obeldesivir
- Where
- 81 sites in Brazil, Bulgaria and 16 more
- Volunteers
- 468 people
- Sponsor
- Gilead Sciences
Methamphetamine-dependence, Rectal Gonorrhea
Inflammation in Methamphetamine and STIs (IMSTI)
This clinical trial aims to investigate the effects of a decline in methamphetamine use on rectal inflammatory cytokine levels, substance use contexts, and HIV/STI risk behavior.
- Conditions
- Methamphetamine-dependence, Rectal Gonorrhea, Rectal Chlamydia
- Trial name
- IMSTI (NCT05162391)
- Testing
- Contingency Management
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Sick Sinus Syndrome, Complete Heart Block
Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.
The number of cardiac implantable electronic devices (CIEDs) implanted each year has grown rapidly over the past two decades. CIED infections, defined as infections involving the generator implant site (pocket) and/or…
- Conditions
- Sick Sinus Syndrome, Complete Heart Block, Syncope, Chronic Systolic Heart Failure
- Trial name
- ENVELOPE (NCT02809131)
- Testing
- polymixin/bacitracin, cephalexin, or levofloxacin, or clindamycin, Saline
- Where
- United States
- Volunteers
- 1,010 people
- Sponsor
- Vanderbilt University Medical Center
Onchocerciasis
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
The primary purpose of this study is to determine a dose of moxidectin for children 4 to 11 years that is equivalent to an 8 mg dose administered for treatment of onchocerciasis in people 12 years and over.
- Trial name
- NCT03962062
- Testing
- Moxidectin
- Where
- Ghana
- Volunteers
- 36 people
- Sponsor
- Medicines Development for Global Health
Human Immunodeficiency Virus Infection
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
Potent HIV suppression with Darunavir-based antiretroviral therapy (ART) will lead to repopulation of gastrointestinal-associated lymphoid tissue (GALT) cluster of differentiation (CD)4+ T-cell populations, normalization of…
- Trial name
- NCT01869634
- Testing
- darunavir with ritonavir and fixed-dose viread+emtricitabine daily
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
B-cell Acute Lymphoblastic Leukemia
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of CTL019 in pediatric patients with r/r B-cell ALL.
- Trial name
- ELIANA (NCT02435849)
- Testing
- CTL019
- Where
- 23 sites in United States, Australia and 9 more
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
HIV-1-infection, COVID-19
HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
HIV CoCo is a European multi-centre, multi-country, retrospective, observational case-control study that will aim to describe clinical outcomes and identify risk factors for People Living With HIV (PLWHIV) who are co-infected…
- Trial name
- HIV CoCo (NCT05481216)
- Testing
- COVID-19, HIV-1 infection
- Where
- 23 sites in Belgium, France and 3 more
- Volunteers
- 2,598 people
- Sponsor
- NEAT ID Foundation